UBS Group
CMMB

UBS Group’s Chemomab Therapeutics CMMB Stock Holding History

UBS Group’s Portfolio CMMB Stock Details CMMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13 Sell
8
-2,245
-100% -$3.84K ﹤0.01% 10316
2025
Q4 		$3.72K Buy
2,253
+2,154
+2,176% +$5.71K ﹤0.01% 8963
2025
Q3 		$260 Hold
99
– – ﹤0.01% 9772
2025
Q2 		$461 Sell
99
-122
-55% -$603 ﹤0.01% 9822
2025
Q1 		$962 Buy
221
+100
+83% +$702 ﹤0.01% 9602
2024
Q4 		$878 Sell
121
-451
-79% -$2.85K ﹤0.01% 9360
2024
Q3 		$3.59K Buy
+572
New +$3.21K ﹤0.01% 8247
2023
Q4 		– Sell
-35
Closed -$126 – 9369
2023
Q3 		$126 Buy
35
+32
+1,067% +$150 ﹤0.01% 8829
2023
Q2 		$16 Sell
3
-100
-97% -$631 ﹤0.01% 8708
2023
Q1 		$653 Sell
103
-1,054
-91% -$8.27K ﹤0.01% 8938
2022
Q4 		$14.8K Sell
1,157
-65
-5% -$561 ﹤0.01% 8045
2022
Q3 		$12K Buy
+1,222
New +$15.7K ﹤0.01% 8150
2022
Q2 		– Sell
-221
Closed -$4K – 10379
2022
Q1 		$4K Sell
221
-240
-52% -$4.73K ﹤0.01% 9277
2021
Q4 		$13K Buy
461
+23
+5% +$816 ﹤0.01% 8440
2021
Q3 		$19K Buy
438
+403
+1,151% +$24.5K ﹤0.01% 7199
2021
Q2 		$3K Sell
35
-174
-83% -$17K ﹤0.01% 8787
2021
Q1 		$24K Buy
+209
New +$41.6K ﹤0.01% 7202
2020
Q2 		– Sell
-34
Closed -$2K – 7972
2020
Q1 		$2K Buy
+34
New +$2.49K ﹤0.01% 7600
2019
Q3 		– Sell
-22
Closed -$6K – 8019
2019
Q2 		$6K Sell
22
-21
-49% -$7.3K ﹤0.01% 7302
2019
Q1 		$19K Buy
+43
New +$21.7K ﹤0.01% 6339

Other funds holding CMMB

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $8.11B AUM 24.74% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
SP
SmartHarvest Portfolios Poulsbo, Washington $240M AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
PIP
Philadelphia Investment Partners Voorhees, New Jersey $147M AUM

UBS Group's CMMB Position: Q1 2026 in Review

UBS Group reduced its Chemomab Therapeutics (CMMB) stake by 100% in Q1 2026, selling an estimated $3.84K and leaving 8 shares worth $13. The position accounts for ﹤0.01% of the portfolio, ranked #10316.

UBS Group first reported a position in CMMB in Q1 2019 and has held it in 20 quarters since. The position peaked at $24K in Q1 2021. 15 funds tracked by Wall St. Rank hold CMMB as of Q1 2026.

  • UBS Group held 8 shares of Chemomab Therapeutics worth $13 as of Q1 2026.
  • UBS Group sold 2,245 Chemomab Therapeutics shares in Q1 2026, an estimated $3.84K.
  • Chemomab Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #10316 holding.
  • UBS Group first reported a position in Chemomab Therapeutics in Q1 2019 and has held it in 20 quarters since.
  • UBS Group's Chemomab Therapeutics position peaked at $24K in Q1 2021.
  • 15 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.